Combined with the results obtained from staining the proliferation marker Ki67, which showed that cells within the tumour sections from AmatuxEDVDox-treated mice had significantly lower proliferation, we have demonstrated that AmatuxEDVs can be used to target mesothelioma cells and deliver therapeutic doses of doxorubicin, resulting in reduced cell proliferation, lower cellular necrosis and suppression of tumour growth. This evidence concerns the gene MKI67 and neoplasm.